146 In the index

Triptorelin TRIP

An FDA-approved hormone-blocking medication used for prostate cancer, early puberty, and endometriosis, working similarly to a related drug called leuprolide. Extensive research supports these approved uses, with an expected initial hormone surge followed by suppression as part of how it works.

Also known as Decapeptyl, Triptoreline, Triptorelina, Arvekap, Triptorelinum, Triptodur, (D-Trp6)-GnRH, tryptorelin

Effects Hormonal

Routes Injectable

Legal status Prescription drug

WADA Banned at all times

Molecular Structure of C₆₄H₈₂N₁₈O₁₃

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C64H82N18O13
Molar mass: 1311.4
CAS: 57773-63-4
PubChem CID: 25074470
IUPAC name: (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
InChIKey: VXKHXGOKWPXYNA-PGBVPBMZSA-N

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 3.75 mg monthly or 11.25 mg every 3 months, depending on formulation

Reported range 3.75-22.5 mg depending on depot formulation and indication

Route Intramuscular injection

Frequency Monthly to every 6 months, depending on depot formulation

Duration Chronic/ongoing (as prescribed)

FDA-approved GnRH agonist (Trelstar) for prostate cancer, precocious puberty, and endometriosis, working similarly to leuprolide.

Where this comes from FDA prescribing information

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.